drugset / Trial / NCT00759642

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

NCT00759642 ↗

Phase 2 Terminated 33 enrolled University of Kansas Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Hormone receptor positive breast cancer is the most common type of breast cancer, comprising 70-80% of all breast cancers. Endocrine therapy is the main type of initial treatment for patients with your type of breast cancer. Endocrine therapy is treatment that tries to remove, or block certain hormones from binding to the cancer cells and thus slow or stop the growth of cancer. Although most patients with your type of breast cancer respond initially to endocrine therapies, it can lose its effectiveness. New therapies for this type of cancer are needed.

Timeline

Start
2009-03
Primary completion
2015-11
Completion
2018-08-20

Outcome

Outcome not reported

Stopped: “IRB decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule 1500 mg Oral

Indications